University of Leicester
Browse

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

Download (416.75 kB)
journal contribution
posted on 2019-10-17, 09:17 authored by HS Walter, S Jayne, SA Rule, G Cartron, F Morschhauser, S Macip, L Karlin, C Jones, C Herbaux, P Quittet, N Shah, CV Hutchinson, C Fegan, Y Yang, S Mitra, G Salles, MJS Dyer
[First paragraph] The inhibitor of Bruton’s tyrosine kinase (BTK) ibrutinib has transformed the treatment of chronic lymphocytic leukemia (CLL); many patients with previously untreatable disease may now enter durable remissions.1,2 Nevertheless, the kinome of ibrutinib is broad, resulting in toxicities including bleeding, arthralgia, diarrhea, hypertension, and atrial fibrillation.3-6 Up to 20% of patients discontinue ibrutinib due to toxicity.7-9 More selective BTK inhibitors (BTKis) include ONO/GS-4059, acalabrutinib, and BGB-3111. Preliminary data indicate that these drugs have comparable activity to ibrutinib, but with reduced toxicities.10-12 However, long-term follow-up and response data have not yet been reported. We provide an updated, 3-year follow-up of treatment efficacy, safety, and laboratory correlates, including baseline mutational profiling of CLL patients in the phase 1 ONO/GS-4059 extension study.

Funding

NGS (Sistemas Genomicos; https://www.sistemasgenomicos.com) was funded by the Cancer Research UK Leicester Centre and supported by the Leicester Experimental Cancer Medicine Centre. This study was funded by Gilead Sciences, Inc. Editorial support was provided by Impact Communication Partners, Inc.

History

Citation

Blood, 2017, 129 (20), pp. 2808-2810

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/Biological Sciences/Molecular & Cell Biology

Version

  • AM (Accepted Manuscript)

Published in

Blood

Publisher

American Society of Hematology

eissn

1528-0020

Copyright date

2017

Available date

2019-10-17

Publisher version

https://ashpublications.org/blood/article/129/20/2808/36109/Longterm-followup-of-patients-with-CLL-treated

Notes

The online version of this article contains a data supplement. https://ashpublications.org/blood/article/129/20/2808/36109/Longterm-followup-of-patients-with-CLL-treated#supplementary-data

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC